View Author
patient myeloma treatment study bortezomib therapy thalidomide novel agents agent novel result trial lenalidomide month effectiveness dexamethasone review health phase evaluation response dasatinib group quality nilotinib companion cancer combination estimate analysis –effectivenes survival regimen table future cost –effectiveness myeloid leukemia outcome myeloma patients companion diagnostics progression melphalan leukemia /refractory prednisone evidence disease blood effect grade myeloid difference second-line strategy hospital diagnostic alternative responder event grade 3 healthcare transplantation imatinib efficacy model utility prognostic factors acquisition costs analyses health care costs scenario pharmacogenomic value maintenance dutch upfront therapy assessment signi ficantly nonresponder impact
4 Most Recent Publications
|
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
(Article)
Gaultney, J.G. Franken, M. Tan, S.S. Orlewska, E. Huijgens, P.C. Sonneveld, P. Uyl-de Groot, C.A. |
2013-02-01
|
|
Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value
(Article)
Gaultney, J.G. Orlewska, E. Sonneveld, P. Uyl-de Groot, C.A. |
2012-06-01
|
|
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
(Article)
Gaultney, J.G. Orlewska, E. Sonneveld, P. Uyl-de Groot, C.A. |
2011-07-01
|
|
Application of cost-effectiveness ana lysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
(Article)
Gaultney, J.G. Sanhueza, E. Janssen, J. Orlewska, E. Uyl-de Groot, C.A. |
2011-03-01
|
